These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Complete protection against a H5N2 avian influenza virus by a DNA vaccine expressing a fusion protein of H1N1 HA and M2e. Park KS; Seo YB; Lee JY; Im SJ; Seo SH; Song MS; Choi YK; Sung YC Vaccine; 2011 Jul; 29(33):5481-7. PubMed ID: 21664216 [TBL] [Abstract][Full Text] [Related]
3. Universal influenza A M2e-HBc vaccine protects against disease even in the presence of pre-existing anti-HBc antibodies. De Filette M; Martens W; Smet A; Schotsaert M; Birkett A; Londoño-Arcila P; Fiers W; Saelens X Vaccine; 2008 Dec; 26(51):6503-7. PubMed ID: 18835315 [TBL] [Abstract][Full Text] [Related]
4. Roles of adjuvant and route of vaccination in antibody response and protection engendered by a synthetic matrix protein 2-based influenza A virus vaccine in the mouse. Mozdzanowska K; Zharikova D; Cudic M; Otvos L; Gerhard W Virol J; 2007 Oct; 4():118. PubMed ID: 17974006 [TBL] [Abstract][Full Text] [Related]
6. Potent immunogenicity and efficacy of a universal influenza vaccine candidate comprising a recombinant fusion protein linking influenza M2e to the TLR5 ligand flagellin. Huleatt JW; Nakaar V; Desai P; Huang Y; Hewitt D; Jacobs A; Tang J; McDonald W; Song L; Evans RK; Umlauf S; Tussey L; Powell TJ Vaccine; 2008 Jan; 26(2):201-14. PubMed ID: 18063235 [TBL] [Abstract][Full Text] [Related]
7. Induction of protection against divergent H5N1 influenza viruses using a recombinant fusion protein linking influenza M2e to Onchocerca volvulus activation associated protein-1 (ASP-1) adjuvant. Zhao G; Du L; Xiao W; Sun S; Lin Y; Chen M; Kou Z; He Y; Lustigman S; Jiang S; Zheng BJ; Zhou Y Vaccine; 2010 Oct; 28(44):7233-40. PubMed ID: 20732469 [TBL] [Abstract][Full Text] [Related]
8. Induction of cross-protective immunity against influenza A virus H5N1 by an intranasal vaccine with extracts of mushroom mycelia. Ichinohe T; Ainai A; Nakamura T; Akiyama Y; Maeyama J; Odagiri T; Tashiro M; Takahashi H; Sawa H; Tamura S; Chiba J; Kurata T; Sata T; Hasegawa H J Med Virol; 2010 Jan; 82(1):128-37. PubMed ID: 19950232 [TBL] [Abstract][Full Text] [Related]
9. Cross-protection against influenza virus infection by intranasal administration of M2-based vaccine with chitosan as an adjuvant. Sui Z; Chen Q; Wu R; Zhang H; Zheng M; Wang H; Chen Z Arch Virol; 2010 Apr; 155(4):535-44. PubMed ID: 20195654 [TBL] [Abstract][Full Text] [Related]
10. Protective immunity against influenza H5N1 virus challenge in mice by intranasal co-administration of baculovirus surface-displayed HA and recombinant CTB as an adjuvant. Prabakaran M; Velumani S; He F; Karuppannan AK; Geng GY; Yin LK; Kwang J Virology; 2008 Oct; 380(2):412-20. PubMed ID: 18786689 [TBL] [Abstract][Full Text] [Related]
11. Protection against influenza A virus by vaccination with a recombinant fusion protein linking influenza M2e to human serum albumin (HSA). Mu X; Hu K; Shen M; Kong N; Fu C; Yan W; Wei A J Virol Methods; 2016 Feb; 228():84-90. PubMed ID: 26615805 [TBL] [Abstract][Full Text] [Related]
12. Immunization with high epitope density of M2e derived from 2009 pandemic H1N1 elicits protective immunity in mice. Zhou C; Zhou L; Chen YH Vaccine; 2012 May; 30(23):3463-9. PubMed ID: 22446634 [TBL] [Abstract][Full Text] [Related]
14. Influenza virus-like particles elicit broader immune responses than whole virion inactivated influenza virus or recombinant hemagglutinin. Bright RA; Carter DM; Daniluk S; Toapanta FR; Ahmad A; Gavrilov V; Massare M; Pushko P; Mytle N; Rowe T; Smith G; Ross TM Vaccine; 2007 May; 25(19):3871-8. PubMed ID: 17337102 [TBL] [Abstract][Full Text] [Related]
15. Characterization of the murine Th2 response to immunization with liposomal M2e influenza vaccine. Adler-Moore J; Munoz M; Kim H; Romero J; Tumpey T; Zeng H; Petro C; Ernst W; Kosina S; Jimenez G; Fujii G Vaccine; 2011 Jun; 29(27):4460-8. PubMed ID: 21545821 [TBL] [Abstract][Full Text] [Related]
16. Comparison of vaccines for induction of heterosubtypic immunity to influenza A virus: cold-adapted vaccine versus DNA prime-adenovirus boost strategies. Lo CY; Wu Z; Misplon JA; Price GE; Pappas C; Kong WP; Tumpey TM; Epstein SL Vaccine; 2008 Apr; 26(17):2062-72. PubMed ID: 18378366 [TBL] [Abstract][Full Text] [Related]
17. Vaccination with whole inactivated virus vaccine affects the induction of heterosubtypic immunity against influenza virus A/H5N1 and immunodominance of virus-specific CD8+ T-cell responses in mice. Bodewes R; Kreijtz JH; Hillaire ML; Geelhoed-Mieras MM; Fouchier RA; Osterhaus AD; Rimmelzwaan GF J Gen Virol; 2010 Jul; 91(Pt 7):1743-53. PubMed ID: 20335492 [TBL] [Abstract][Full Text] [Related]
18. A live attenuated H1N1 M1 mutant provides broad cross-protection against influenza A viruses, including highly pathogenic A/Vietnam/1203/2004, in mice. Xie H; Liu TM; Lu X; Wu Z; Belser JA; Katz JM; Tumpey TM; Ye Z J Infect Dis; 2009 Dec; 200(12):1874-83. PubMed ID: 19909080 [TBL] [Abstract][Full Text] [Related]
19. Vaccination focusing immunity on conserved antigens protects mice and ferrets against virulent H1N1 and H5N1 influenza A viruses. Price GE; Soboleski MR; Lo CY; Misplon JA; Pappas C; Houser KV; Tumpey TM; Epstein SL Vaccine; 2009 Nov; 27(47):6512-21. PubMed ID: 19729082 [TBL] [Abstract][Full Text] [Related]
20. AF03-adjuvanted and non-adjuvanted pandemic influenza A (H1N1) 2009 vaccines induce strong antibody responses in seasonal influenza vaccine-primed and unprimed mice. Caillet C; Piras F; Bernard MC; de Montfort A; Boudet F; Vogel FR; Hoffenbach A; Moste C; Kusters I Vaccine; 2010 Apr; 28(18):3076-9. PubMed ID: 20193791 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]